Skip to Content

Microbial Glycobiology

Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland

Position Description:

This research opportunity will be within the Laboratory of Bacterial Polysaccharides at CBER/FDA with the goal of using recombinant technologies, metabolic engineering and/ synthetic biology as tools to improve the understanding of glycoconjugate vaccine synthesis and immunology. The selected participant will receive mentoring on fulfilling the project, which will also include collaboration with investigators within and external to the FDA. The participant will be studying Glycoengineered Outer Membrane Vesicles (OMV) as an alternative platform to generate glycoconjugate vaccines that target encapsulated pathogens. The participant will generate a prototype expression system for Streptococcus pyogenes Group A carbohydrate (GAC) in Escherichia coli (GAC-geOMV), and test and evaluate the immune response of these purified GAC-geOMV.

The position is available for a start date of September 1, 2020.

Qualifications:

Applicants should have earned a PhD in biochemistry, molecular biology, or related field within the last 5 years and have a working knowledge of glycobiology and mass spectrometry.

To Apply:

Interested persons should contact: Dr. M. Florencia Haurat, Department of Molecular Microbiology, Washington University School of Medicine St Louis, 660 South Euclide Avenue, Campus Box 8230, St Louis, MO 63110,   Email: mhaurat@wustl.edu

 

 

The FDA is dedicated to building a diverse community in its training and employment programs. Applicants must have resided in the USA at least 3 of the last 5 years. Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA.

This post will be available until August 8, 2020 or until filled.

The NIH is dedicated to building a diverse community in its training and employment programs.